Anxiety and Sleep Followed Different Patterns in a Retrospective CBD Series
A retrospective CBD series reported improvements in anxiety more consistently than in sleep. Combining the outcomes into one success claim would hide that difference and overstate what an uncontrolled clinical record review can establish.
The reported percentages described observed patients
The review summarizes Shannon and colleagues’ series of 72 adults presenting with anxiety or sleep concerns. In the first month, anxiety scores improved in 79.2% and sleep scores in 66.7%.
The review describes anxiety improvement as more sustained, with less consistent sleep findings. These percentages describe changes in the observed series; they are not placebo-adjusted treatment response rates.
A common intervention does not merge the outcomes
Anxiety and sleep can interact, but improvement in one is not proof of improvement in the other. Different trajectories can be clinically important even when the same preparation was used.
The retrospective design lacked a placebo comparison. Changes could reflect treatment, concurrent care, expectations, natural fluctuation or other influences. The series cannot isolate those possibilities as a randomized trial might.
Do not turn an early change into durable efficacy
A first-month observation should remain attached to that interval. Later variability prevents assuming that every initial improvement continued unchanged.
The appropriate research question is whether controlled studies reproduce the outcome-specific patterns. This review summary identifies a preliminary signal and its limitations, without establishing that CBD reliably treats both conditions or predicting the response of a particular person.
Related: Why outcomes must remain specific to the tested domain.
Research cited
Șolea R; Șerban E; Călugăr-Solea SF; et al.. Pharmaceuticals (2026). Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders.
